A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase 3 Trial Evaluating the Efficacy, Safety, and Immunogenicity of GR1802 Injection in Patients With Moderate to Severe Atopic Dermatitis
Latest Information Update: 25 Jan 2024
At a glance
- Drugs Telikibart (Primary)
 - Indications Atopic dermatitis
 - Focus Registrational; Therapeutic Use
 - Sponsors Genrix (Shanghai) Biopharmaceuticals
 
Most Recent Events
- 25 Jan 2024 New trial record